LDS/Medical Tests/Methylation Cancer Marker Detection in Cell-free Circulating Tumor DNA (Northstar Select and Response™)

Methylation Cancer Marker Detection in Cell-free Circulating Tumor DNA (Northstar Select and Response™)

Cancer develops largely from genetic mutations in oncogenes and tumor suppressor genes, but epigenetic mechanisms such as DNA methylation also play a critical role in tumorigenesis. DNA methylation refers to the addition of a methyl (CH₃) group to the 5th carbon of cytosine residues, mediated by DNA methyltransferases (DNMTs). This chemical modification alters gene expression without changing the underlying DNA sequence. Aberrant methylation patterns, particularly hypermethylation of tumor suppressor genes, are strongly associated with cancer initiation and progression.

The Northstar Response™ test is a next-generation sequencing (NGS)–based assay that evaluates methylation patterns in circulating tumor DNA (ctDNA) released into the bloodstream. By detecting hundreds of genomic loci uniquely methylated in cancer cells, it provides a highly sensitive and specific means of cancer detection. Published data indicate that methylation analysis can be up to 10 times more sensitive than single-nucleotide variant (SNV) based ctDNA monitoring.

This test enables not only cancer detection but also dynamic monitoring. Changes in the quantity of methylated ctDNA correspond to tumor burden, with rising scores suggesting recurrence or progression and declining scores reflecting treatment response.

  • Noninvasive detection and monitoring of solid tumors
  • Assists in prognostication and therapeutic planning
  • Valuable for surveillance in individuals with a strong family history of cancer or prior malignancy

Decreased methylation score: Reduction in methylated ctDNA molecules compared with prior measurement, suggesting decreased tumor fraction or treatment response.

Increased methylation score: Elevated levels of methylated ctDNA, indicating increased tumor burden, progression, or recurrence. Stable methylation score: Suggests no significant change in tumor fraction compared to baseline.

No established normal reference ranges; results are interpreted relative to patient’s baseline and serial measurements

Next-generation sequencing (NGS) with methylation profiling.

Whole blood, EDTA.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable
Tumor biopsy for histopathology and genomic profiling, individual tumor markers.
1-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login